An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: Evidence for modifier effects

American Journal of Human Genetics

Volumn 63, Issue 4, 1998, Pages 1025-1035

  Webster, Andrew R ^a,b   Richards, Frances M ^c   MacRonald, Fionae ^c   Moore, Anthony T ^a   Maher, Eamonn R ^c  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GLUTATHIONE TRANSFERASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SUSCEPTIBILITY; CHILD; ENVIRONMENTAL FACTOR; FAMILIAL CANCER; FEMALE; GENETIC VARIABILITY; HEMANGIOMATOSIS; HEREDITY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PHENOTYPE; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; VON HIPPEL LINDAU DISEASE;

EID: 0032231366     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/302037     Document Type: Article

References (36)

1. Agúndez JAG, Ledesma MC, Benítez J, Ladero JM, Rodriguez-Lescure A, Diaz-Rubio E, Diaz-Rubio M (1995) CYP2D6 genes and risk of liver cancer. Lancet 345:830-831
2. Agúndez JAG, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA, et al (1996) Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers. Pharmacogenetics 6:501-512
3. Brauch H, Kishida T, Glavac D, Chen F, Pausch F, Hofler H, Latif F, et al (1995) von Hippel Lindau disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet 95:551-556
4. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean D, Gnarra JR, et al (1995) Germline mutations in the von Hippel Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 5:66-75
5. Clifford SC, Prowse AH, Affara NA, Buys CHCM, Maher ER (1998) Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 22:200-209
6. Crossey PA, Foster K, Richards FM, Phipps ME, Latif F, Tory K, Jones MH, et al (1994a) Molecular genetic investigation of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet 93:53-58
7. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, et al (1994b) Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum Mol Genet 3:1303-1308
8. Daiy AK, Thomas DJ, Cooper J, Pearson WR, Neal DE, Idle JR (1993) Homozygous deletion of gene for glutathione-Stransferase M1 in bladder cancer. Br Med J 307:481-482
9. Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, Borenstein N, et al (1993) Genetic identification of Mom-1, a major modifier locus affecting Mm-induced intestinal neoplasia in the mouse. Cell 75:631-639
10. Easton DF, Ponder MA, Huson SM, Ponder BAJ (1993) An analysis of variation in expression of neurorlbromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 53:305-313
11. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MMF, Crossey PA, Richards FM, et al (1994) Somatic mutations of the von Hippei-Lindau disease tumor suppressor gene in nonfamilial clear cell renal carcinoma. Hum Mol Genet 3:2169-2173
12. Gnarra JR, Tory K, Weng Y, Schimdt L, Wei MH, Li H, Latif F, et al (1994) Mutations of the VHL tumor suppressor gene in renal carcinoma. Nat Genet 7:85-90
13. Gould KA, Dietrich WF, Borenstein N, Lander ES, Dove WF (1996) Mom-1 is a semi-dominant modifier of intestinal adenoma size and multiplicity in Min/+ mice. Genetics 144:1769-1776
14. Herman JG, Latif F, Weng YK, Lerman MI, Zbar B, Liu S, Samid D, et al (1994) Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinomas. Proc Natl Acad Sci USA 91:9700-9704
15. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Vainio H (1993) Polymorphism in CYPlAl and CYP2D6 genes; possible association with susceptibility to lung cancer. Environ Health Perspect 101 Suppl3:109-112
16. Jones MH, Yamakawa K, Nakamura Y (1992) Isolation and characterization of 19 dinucleotide repeat polymorphisms on chromosome 3p. Hum Mol Genet 1:131-133
17. Kanno H, Kondo K, Ito S, Yamamoto I, Fujii S, Torigoe T, Sakai N, et al (1994) Somatic mutations of the von HippeiLindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res 54:4845-4847
18. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823
19. Latif F, Tory K, Gnarra J, Yao M, Duh F-M, Orcutt ML, Stackhouse T, et al (1993) Identification of the von HippelLindau disease tumor suppressor gene. Science 260:1317-1320
20. Maher ER, Kaelin WG (1997) von Hippel-Lindau disease. Medicine 76:381-391
21. Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ, Moore AT (1996) Phenotypic expression in von Hippel-Lifldau disease: correlations with germline VHL gene mutations. J Med Genet 33:328-332
22. Maher ER, Yates JRW, Harries R, Benjamin C, Harris R, Ferguson-Smith MA (1990) Clinical features and natural history of von Hippei-Lindau disease. Q J Med 77:1151-1163
23. Obersrraβ J, Reifenberger G, Reifenberger J, Wechsler W, Collins VP (1996) Mutation of the von Hippei-Lindau tumor suppressor gene in capillary haemangioblastomas of the central nervous system. J Pathol 179:151-156
24. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, Lenoir GM, et al (1996) Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 12:309-311
25. Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA, et al (1997) Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 60:765-771
26. Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanan E, Hirvonen A, Pelkonen O (1995) Diagnosis of polymorphisms in carcinogen activating and inactivating enzymes and cancer susceptibility-a review. Gene 159:113-121
27. Richards FM, Crossey PA, Phipps ME, Foster K, Latif F, Evans G, Sampson J, et al (1994) Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene Hum Mol Genet 3:595-598
28. Richards FM, Payne SJ, Zbar B, Affara NA, Ferguson-Smith MA, Maher ER (1995) Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet 4:2139-2143
29. Richards FM, Schofield PN, Fleming S, Maher ER (1996) Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 5:639-644
30. Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
31. Smith CAD, Moss JE, Gough AC, Spurr NK, Wolf CR (1992) Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ Health Perspect 98:107-112
32. Whaley JM, Naglich J, Gelbert L, Hsia YE, Lamiell JM, Green JS, Collins D, et al (1994) Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 55:1092-1102
33. Wolf CR, Smith CAD, Forman D (1994) Metabolic polymorphisms in carcinogen metabolising enzymes and cancer susceptibility. Br Med Bull 50:718-731
34. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, et al (1996) Germline mutations in the von Hippel Lindau disease (VHL) gene in families from North America, Europe and Japan. Hum Mutat 8:348-357
35. Zhong S, Howie AF, Ketterer B, Taylor J, Hayes JD, Beckett GJ, Wathen CG, et al (1991) Glutathione-S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 12:1533-1537
36. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK (1993) Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14:1821-1824